Ixazomib citrate

SKU: orb1298968

Description

Ixazomib citrate (MLN9708) is an orally administered prodrug that is rapidly hydrolyzed to the active proteasome inhibitor ixazomib. This second-generation inhibitor demonstrates potent antineoplastic activity in vitro and in vivo, primarily applied in multiple myeloma research and investigations of proteasome function.

Research Area

Cell Biology, Protein Biochemistry

Key Properties

• CAS Number: 1239908-20-3
• MW: 517.12
• Purity: >99.99% (May vary between batches)
• Formula: C₂₀H₂₃BCl₂N₂O₉
• SMILES: CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1
• Target: Proteasome,Autophagy
• Solubility: DMSO:100 mg/mL (193.38 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (7.74 mM)

Bioactivity

• Target IC50:
  20S proteasome β1:31 nM |20S proteasome β2:3500 nM|20S proteasome β5:3.4 nM
• In Vivo:
  In animal tumor model studies, Ixazomib is well tolerated and inhibits tumor growth with significantly reduced tumor recurrence. A head-to-head analysis of Ixazomib versus bortezomib showed a significantly longer survival time in mice treated with Ixazomib than mice receiving bortezomib.
• In Vitro:
  Treatment of MM cells with MLN2238 predominantly inhibits chymotrypsin-like activity of the proteasome and induces accumulation of ubiquitinated proteins. MLN2238 inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies without affecting the viability of normal cells.

Storage & Handling

• Storage: keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

MLN9708, MLN-9708, MLN 9708, Ixazomib, Ixazomib citrate, Ixazomib Citrate, Inhibitor, inhibit, Autophagy, Proteasome

Compound Identifiers

PubChem CID

56844015